Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of durvalumab monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
2014-003295-23Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by AstraZeneca. Primary endpoint: Objective response rate. Started Jan 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2014-003295-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003295-23.